The success of novel immune modulators, such as inhibitors of cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death ligand-1 (PD-L1), in treating certain types of cancers, has recently led to the emergence of ‘immuno radio-oncology’ as a new field of research. This evidence concerns the gene CD274 and cancer.